metallopeptidas
angiotensinconvert
enzym
identifi
function
receptor
sarscov
interact
domain
viral
glycoprotein
interact
subsequ
infect
block
solubl
form
antibodi
express
cell
line
correl
suscept
sarscov
sdriven
infect
suggest
must
major
receptor
sarscov
turn
suggest
sarscov
protein
may
consid
attract
target
therapeut
intervent
interestingli
express
posit
correl
differenti
state
human
airway
epithelia
undifferenti
cell
express
littl
poorli
infect
sarscov
well
differenti
cell
express
readili
infect
acid
fragment
protein
correspond
residu
bind
effici
full
domain
fact
fragment
block
proteinmedi
infect
inhibitori
concentr
less
nm
full
domain
nm
also
human
monoclon
antibodi
protein
domain
block
associ
sarscov
indic
bind
site
could
target
drug
develop
smallmolecularweight
inhibitor
found
interact
activ
catalyt
site
ethylamino
acid
describ
whether
inhibit
sarscov
infect
yet
demonstr
wherea
domain
glycoprotein
determin
viru
attach
host
cell
subsequ
fusion
process
govern
conform
chang
two
heptad
region
hr
n
hrc
within
domain
result
format
bundl
trimer
dimer
system
peptid
map
shown
site
interact
region
residu
residu
also
shown
peptid
deriv
region
inhibit
sarscov
infect
micromolar
rang
bound
high
affin
peptid
region
figur
could
bind
region
therebi
interf
conform
chang
lead
bundl
format
figur
therewith
associ
fusion
process
obvious
interact
may
view
attract
target
design
potent
peptidetyp
sarscov
entri
inhibitor
reminisc
peptid
enfuvirtid
develop
fusion
inhibitor
latter
could
inhibit
fusion
sarscov
target
cell
appar
low
effici
therapeut
meaning
recent
simmon
colleagu
suggest
follow
receptor
bind
induc
conform
chang
glycoprotein
third
step
would
involv
viral
entri
process
name
cathepsinl
proteolysi
within
endosom
demonstr
cathepsinlspecif
inhibitor
mdl
also
known
calpain
inhibitor
iii
cho
time
inhibit
cathepsinl
activ
proteinmedi
infect
nm
respect
addit
calpain
inhibitor
iii
calpain
inhibitor
describ
inhibitor
sarscov
replic
select
select
index
calpain
inhibitor
vi
cho
figur
follow
entri
sarscov
host
cell
genom
plusstrand
rna
translat
produc
two
larg
overlap
replicas
polyprotein
process
function
polypeptid
extens
proteolyt
cleavag
mainli
sar
proteas
also
call
main
proteas
mpro
cleav
replicas
polyprotein
mani
conserv
site
gener
function
protein
necessari
viru
replic
mpro
quickli
recogn
attract
target
develop
antisarscov
agent
propos
compound
proven
activ
rhinoviru
proteas
could
modifi
order
make
activ
cov
sarscov
first
modif
methylen
group
pfluorophenylalanin
residu
remov
result
model
structur
sarscov
mpro
crystal
structur
sarscov
mpro
complex
variou
substrat
analog
hexapeptidyl
chloromethyl
keton
figur
azapeptid
epoxid
determin
recombin
sarscov
mpro
success
clone
express
inform
thu
gather
mode
inhibitor
bind
enzym
catalysi
help
provid
structur
basi
ration
drug
design
number
peptidomimet
compound
aziridinyl
peptid
ketoglutamin
analog
chymotrypsinlik
proteas
inhibitor
peptid
anilid
report
inhibitor
sarscov
mpro
niclosamid
anilid
figur
ki
prove
potent
competit
inhibitor
also
sever
nonpeptid
compound
describ
inhibitor
sarscov
mpro
etacryn
acid
deriv
etacryn
acid
amid
ki
isatin
deriv
valu
rang
hexachlorophen
deriv
valu
rang
natur
product
tea
howev
none
case
ascertain
whether
compound
also
effect
inhibit
sarscov
infect
cell
cultur
except
two
chymotrypsinlik
proteas
inhibitor
found
inhibit
sarscov
cell
cultur
rel
high
concentr
respect
case
proteas
inhibitor
shown
inhibit
sarscov
proteas
activ
viru
replic
cell
cultur
dipeptid
inhibitor
shown
figur
found
inhibit
proteas
ki
inhibit
viru
replic
vero
cell
effect
concentr
toxic
host
cell
concentr
select
index
cinanserin
sq
well
character
serotonin
antagonist
figur
anoth
exampl
inhibitor
sarscov
replic
may
act
via
inhibit
proteas
enzym
valu
reduct
viral
rna
infecti
particl
rang
final
octapeptid
design
sarscov
mpro
name
avlqsgfr
report
inhibit
sarscov
replic
vero
cell
cytotox
thu
establish
select
index
greater
whether
highli
select
antivir
effect
actual
mediat
inhibit
sarscov
mpro
ascertain
studi
addit
plpro
encod
sarscov
genom
sarscov
plpro
process
replicas
polyprotein
three
conserv
cleavag
site
thu
gener
nonstructur
protein
recent
demonstr
sarscov
plpro
also
deubiquitin
activ
possibl
sarscov
plpro
could
deubiquitin
host
viral
protein
ad
higher
level
function
complex
enzym
principl
elev
valu
sarscov
plpro
potenti
target
therapeut
intervent
sarscov
encod
helicas
must
unwind
doublestrand
rna
helic
viral
replic
cycl
helicas
akin
herpesvir
dna
helicas
also
possess
ntpase
activ
may
therefor
term
ntpasehelicas
sarscov
ntpasehelicas
consid
potenti
target
develop
antisarscov
agent
agent
could
theori
target
three
major
domain
enzym
ntermin
metalbind
domain
hing
domain
ntpasehelicas
domain
bananin
figur
three
deriv
iodobananin
vanillinbananin
eubananin
shown
inhibit
atpas
helicas
activ
sarscov
ntpasehelicas
valu
atpas
activ
rang
bananin
also
found
inhibit
sarscov
replic
fetal
rhesu
kidney
frhk
cell
less
cytotox
concentr
thu
exhibit
select
index
whether
antivir
effect
obtain
cell
cultur
causal
link
inhibit
ntpasehelicas
ascertain
sarscov
rnadepend
rna
polymeras
rdrp
due
pivot
role
viral
replic
repres
anoth
potenti
target
antisar
therapi
enzym
figur
contain
hydrophob
pocket
nonnucleosid
inhibitor
similar
proven
effect
hepatit
c
viru
hcv
polymeras
revers
transcriptas
fact
nonnucleosid
revers
transcriptas
inhibitor
shown
evid
inhibitori
effect
sarscov
rdrp
activ
intrigu
purif
fulllength
sarscov
rdrp
unstabl
hydrolyt
cleav
three
fragment
ntermin
fragment
middl
fragment
ctermin
fragment
compris
catalyt
domain
caus
cleavag
unclear
clear
whether
cleavag
also
occur
viral
life
cycl
present
nucleosid
analog
recogn
specif
inhibitor
sarscov
rdrp
accredit
antihcv
antisarscov
effect
sarscov
prove
activ
select
index
howev
whether
antivir
effect
mediat
inhibit
viral
rdrp
ascertain
given
larg
genom
sarscov
cov
need
discontinu
transcript
gener
subgenom
transcript
could
expect
encod
novel
rnaprocess
function
inde
number
protein
identifi
put
exonucleas
endoribonucleas
put
rna
methyltransferas
rna
endonucleas
activ
unusu
among
positivestrand
rna
virus
suggest
specif
occur
sarscov
replic
could
consid
target
antivir
drug
develop
pertain
particular
endoribonucleas
specif
cleav
rna
unpair
uridyl
residu
role
consist
six
subunit
arrang
dimer
trimer
cov
infect
process
still
remain
elucid
mention
human
monoclon
antibodi
mab
domain
protein
sarscov
block
associ
host
cell
receptor
mab
concern
immunoglobulin
ig
evalu
immunoprophylact
efficaci
vivo
mous
model
given
prophylact
mice
dose
therapeut
achiev
human
viral
replic
reduc
four
order
magnitud
assay
limit
result
demonstr
vast
major
sarscov
isol
thu
far
remain
sensit
outbreak
set
earli
rapid
genotyp
gene
fragment
encod
epitop
provid
accur
guid
instal
immunoprophylaxi
data
gener
human
mab
sarscov
ferret
also
point
feasibl
immunoprophylaxi
human
mab
control
human
sarscov
infect
similar
observ
mous
model
demonstr
primari
infect
sarscov
provid
protect
reinfect
antibodi
alon
protect
viral
replic
suggest
vaccin
induc
neutral
antibodi
strategi
immunoprophylaxi
perhap
immunotherapi
like
effect
sar
sarscovinfect
patient
spontan
recov
recov
patient
higher
sustain
level
n
glycoproteinspecif
antibodi
respons
suggest
antibodi
respons
like
play
import
role
determin
ultim
diseas
outcom
sarscovinfect
patient
would
therefor
unreason
expect
antibodi
sarscov
present
convalesc
plasma
may
favor
influenc
cours
sar
interest
hypothesi
deriv
experi
gather
hiv
may
propos
antibodi
toward
carbohydratehidden
immunogen
epitop
sarscov
envelop
may
confer
immunoprophylact
well
immunotherapeut
approach
toward
cov
variou
envelop
viru
infect
enabl
approach
carbohydratebind
agent
hippeastrum
hybrid
amarylli
galanthu
nivali
snowdrop
urtica
dioica
mannos
nacetylglucosaminebind
lectin
could
use
caus
delet
upon
repeat
exposur
passag
glycosyl
site
sarscov
envelop
order
expos
carbohydratehidden
epitop
activ
vaccin
passiv
antibodi
immun
respons
shortli
sarscov
identifi
caus
agent
sar
cinatl
colleagu
first
note
interferon
ifn
inhibit
replic
sarscov
cell
cultur
vitro
potent
either
observ
subsequ
confirm
sever
studi
exhibit
potent
antivir
activ
dose
shown
accept
safeti
profil
also
show
vitro
inhibitori
effect
start
concentr
iuml
contrast
type
ifn
type
ii
ifn
littl
inhibitori
effect
sarscov
replic
human
mxa
protein
one
promin
protein
induc
nevertheless
interfer
sarscov
replic
observ
vero
cell
stabli
express
mxa
impli
ifninduc
protein
must
respons
strong
inhibitori
activ
sarscov
conjunct
found
synergist
inhibit
replic
sarscov
vero
cell
preliminari
uncontrol
studi
ifn
synthet
design
repres
consensu
suggest
type
ifn
combin
corticosteroid
might
effect
vivo
treatment
sar
furthermor
cpg
oligodeoxynucleotid
abl
induc
human
peripher
blood
mononuclear
cell
pbmc
produc
high
level
accredit
strong
activ
sarscov
vitro
prophylact
rather
therapeut
agent
ifn
may
highest
util
prophylaxi
earli
postexposur
manag
sar
pegyl
peg
shown
reduc
viral
replic
excret
viral
antigen
express
type
pneumocyt
attend
pulmonari
damag
cynomolg
macaqu
infect
experiment
sarscov
commerci
avail
treatment
hcv
gener
use
combin
ribavirin
hepat
b
well
commerci
avail
ifn
eg
could
consid
prevent
andor
earli
postexposur
treatment
sar
reemerg
rna
interfer
rnai
defin
silenc
gene
express
degrad
target
rna
rnai
broken
two
main
phase
first
phase
long
doublestrand
rna
dsrna
process
dicer
rnase
iii
enzym
duplex
short
interf
rna
sirna
nucleotid
length
exogen
synthet
sirna
also
incorpor
rnainduc
silenc
complex
risc
therebi
bypass
requir
dsrna
process
dicer
second
phase
helicas
present
risc
unwind
duplex
sirna
pair
mean
unwound
antisens
strand
target
messeng
rna
mrna
bear
high
degre
sequenc
complementar
sirna
rnase
slicer
within
risc
proce
degrad
target
mrna
site
bound
sirna
nucleotid
upstream
residu
sirnatarget
mrna
duplex
thu
sirna
develop
target
replicas
gene
sarscov
genom
therebi
silenc
express
cell
cultur
potent
sirna
inhibitor
sarscov
vitro
ie
sirna
duplex
forward
sequenc
forward
sequenc
target
sarscov
genomeat
protein
region
respect
evalu
efficaci
rhesu
macaqu
sar
model
found
provid
relief
sarscov
infectioninduc
fever
diminish
sarscov
level
reduc
acut
diffus
alveolar
damag
sign
toxic
observ
sirna
concern
whether
sar
conquer
sirna
approach
remain
proven
howev
therefor
sirna
deliveri
form
optim
effect
target
within
sarscov
genom
identifi
sinc
sirna
least
second
stage
action
obey
antisens
principl
antisens
strategi
base
peptideconjug
antisens
phosphorodiamid
morpholino
oligom
ppmo
also
deserv
closer
attent
grow
number
compound
identifi
sarscov
replic
inhibitor
exhibit
mechan
action
divers
larg
unexplor
greater
agent
test
sarscov
vero
cell
approxim
compound
found
activ
less
equal
potent
inhibitor
select
index
emerg
valinomycin
peptid
insecticid
act
potassium
ion
transport
figur
inhibitori
effect
sarscov
replic
select
index
valu
low
observ
varieti
compound
includ
vancomycin
eremomycin
teicoplanin
aglycon
deriv
mannosespecif
plant
lectin
deriv
g
nivali
hippeastrum
hybrid
allium
porrum
leek
mode
action
compound
assess
tempt
specul
interfer
bind
glycoprotein
host
cell
isati
indigotica
root
phenol
chines
herb
frequent
use
prevent
sar
sar
outbreak
china
hong
kong
taiwan
indigotica
root
radix
isatidi
nativ
china
indigotica
root
extract
sever
compound
indigo
sinigrin
aloeemodin
hesperetin
isol
inhibit
cellfre
cellbas
cleavag
activ
sar
mpro
valu
rang
inhibitori
effect
sarscov
replic
cell
cultur
ie
vero
cell
determin
studi
cytotox
determin
howev
base
ratio
cellbas
cleavag
hesperetin
appear
select
select
index
glycyrrhizin
anoth
plant
product
isol
licoric
root
glycyrrhiza
radix
known
antiinflammatori
substanc
chines
medicin
glycyrrhizin
consist
one
molecul
glycyrrhetin
acid
link
two
molecul
glucuron
acid
figur
long
sinc
recogn
antivir
substanc
activ
vitro
dna
rna
virus
includ
hiv
glycyrrhizin
also
shown
inhibit
replic
sarscov
concentr
would
difficult
achiev
vivo
introduct
certain
chemic
modif
prove
possibl
increas
antivir
potenc
glycyrrhizin
modif
also
increas
cytotox
select
index
glycyrrhizin
deriv
reduc
compar
glycyrrhizin
select
index
potent
select
inhibit
sarscov
replic
also
shown
aurintricarboxyl
acid
ata
report
valu
vero
cell
mgml
respect
thu
select
index
ata
estim
antisarscov
activ
ata
tent
attribut
inhibitori
effect
viral
rdrp
recogn
howev
ata
commonli
repres
monomer
structur
actual
occur
heterogen
mixtur
polym
figur
abl
bind
inhibit
varieti
protein
cellular
process
ata
sinc
long
known
inhibitor
hiv
replic
antihiv
activ
least
partial
mediat
specif
interact
hiv
cell
receptor
ribavirin
anoth
compound
long
sinc
known
broadspectrum
antivir
agent
target
inosin
monophosph
imp
dehydrogenas
key
enzym
involv
de
novo
biosynthesi
gtp
show
meaning
activ
sarscov
replic
cell
cultur
determin
viru
yield
reduct
vero
cell
select
index
comparison
mizoribin
also
assum
act
monophosphoryl
form
inhibitor
imp
dehydrogenas
exhibit
select
index
although
find
legitim
use
ribavirin
mizoribin
figur
singl
agent
treatment
sar
point
imp
dehydrogenas
potenti
target
develop
potent
antisarscov
agent
chloroquin
anoth
old
compound
best
known
antimalari
effect
also
accredit
antivir
antiinflammatori
effect
recommend
potenti
use
prefer
combin
antivir
treatment
aid
well
sar
chloroquin
figur
found
inhibit
sarscov
replic
vero
cell
select
index
inhibitori
effect
observ
cell
treat
drug
either
exposur
viru
chloroquin
inhibit
sarscov
vitro
approxim
plasma
concentr
chloroquin
reach
treatment
acut
malaria
inhibit
sarscov
infect
vitro
also
report
nitric
oxid
gener
compound
snitrosonacetylpenicillamin
snap
high
select
index
low
niclosamid
figur
exist
antihelminth
drug
abl
inhibit
replic
sarscov
vero
cell
select
could
therefor
estim
hiv
proteas
inhibitor
nelfinavir
lopinavir
report
inhibit
replic
sarscov
vero
cell
cell
respect
vitro
activ
sarscov
demonstr
lopinavir
concentr
comparison
ribavirin
yamamoto
colleagu
abl
find
select
antivir
effect
lopinavir
nelfinavir
found
select
index
preliminari
clinic
trial
treatment
sar
lopinavir
boost
ritonavir
point
appar
favor
clinic
respons
detail
knowledg
molecular
structur
function
sarsencod
protein
except
mpro
lack
mean
thu
far
success
attempt
made
ration
design
antisarscov
compound
antivir
compound
thu
far
found
effect
sarscov
evalu
previous
shown
analog
compound
shown
previous
effect
virus
sarscov
particular
hiv
could
postul
becom
potenti
antisar
candid
drug
sarscov
inhibitor
possess
select
index
greater
equal
importantli
much
higher
abl
achiev
suffici
high
plasma
tissu
drug
level
upon
system
administr
thu
qualifi
potenti
antisar
drug
candid
calpain
inhibitor
inhibitor
exampl
dipeptid
inhibitor
shown
figur
exhibit
select
index
greater
also
octapeptid
avlqsgfr
select
index
seem
quit
promis
follow
propos
criteria
thu
would
number
miscellan
compound
valinomycin
niclosamid
nelfinavir
equal
greater
import
proof
efficaci
sar
vivo
set
remain
provid
aforement
compound
proof
principl
exist
human
mab
sirna
mean
sarscov
similar
cov
reemerg
attempt
could
immedi
undertaken
prevent
andor
treat
infect
human
mab
ifn
andor
sirna
commerci
avail
present
ifn
etc
possibl
consid
best
choic
curb
sar
strike
final
thu
far
appli
sever
viral
ie
hiv
hcv
infect
could
recommend
other
ie
avian
influenza
drug
combin
therapi
certainli
repres
valuabl
option
manag
sarscov
infect
drug
combin
approach
allow
individu
drug
show
synergist
antivir
effect
therebi
reduc
likelihood
drug
resist
develop
admittedli
far
recogn
problem
treatment
sar
hard
predict
whether
sarscov
similar
cov
would
strike
futur
make
imposs
specul
field
evolv
next
year
howev
avian
influenza
ought
better
prepar
therefor
attempt
continu
develop
appropri
mean
prevent
andor
treat
sarscov
infect
develop
adequ
vaccin
sar
discuss
remain
cours
mandatori
addit
prophylactictherapeut
option
duli
explor
includ
besid
human
mab
ifn
sirna
also
lowmolecularweight
sarscov
inhibitor
target
specif
process
involv
viral
replic
cycl
ie
viral
entri
cell
proteolyt
cleavag
rna
replic
transcript
